Evidence map›Paper›PMID 31881335›Full record

ArticleThe Journal of molecular diagnostics : JMD2020

Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform.

Jamal K Benhamida, Jaclyn F Hechtman, Khedoudja Nafa, Liliana Villafania, Justyna Sadowska, Jiajing Wang, Donna Wong, Ahmet Zehir, Liying Zhang, Tejus Bale and 2 more

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
    Trial
  2. Article
  3. MLH1 promoter methylation in pancreatic ductal adenocarcinoma: frequent but not prognostic.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Low-Grade Fibro-Osseous Lesions With Isolated Chromosome 12 Chromothripsis: A Distinct Entity Or a Low-Grade Central Osteosarcoma With a Novel Driver?Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
  6. Beyond Hybrid Morphology: A Large Series of Fusion-Driven Benign Peripheral Nerve Sheath Tumors Including 5 Tumors With Novel Fusions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A Rapid and Reliable Test forDiagnostics (Basel, Switzerland) · 2025
    Article
  13. Article
  14. Article
  15. Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Recurrent TRAK1::RAF1 Fusions in pediatric low-grade gliomas.Brain pathology (Zurich, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jamal K BenhamidaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: benhamij@mskcc.org.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Khedoudja NafaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Liliana VillafaniaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Justyna SadowskaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jiajing WangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Donna WongDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ahmet ZehirDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Liying ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Tejus BaleDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Maria E ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Clinical testing for MLH1 promoter hypermethylation status is important in the workup of patients with MLH1-deficient colorectal and uterine carcinomas when evaluating patients for Lynch syndrome. Current assays use single gene-based methods to assess promoter hypermethylation. Herein, we describe the development and report the performance of a clinical assay for MLH1 promoter hypermethylation using the Infinium methylationEPIC (850k) bead-array platform. Using four cytosine-guanine dinucleotide (CpG) sites within the MLH1 gene promoter, a qualitative MLH1 promoter hypermethylation assay was developed and validated using 63 gastrointestinal and uterine carcinoma samples of known hypermethylation status based on a pyrosequencing reference test. The array-based method achieves clinically robust and reproducible results at an analytical sensitivity level of 8%. Of importance, the 850k array contains probes targeting >850,000 additional CpG sites across the genome, covering sites in most known genes as well as important enhancer regions provided by the Encyclopedia of DNA Elements and Functional Annotation of The Mammalian Genome projects. Thus, the testing modality presented may also be applied to determine the methylation status of other clinically relevant genes or regulatory regions, potentially providing a single laboratory testing workflow for all clinical methylation assays. Furthermore, the concomitant acquisition of genome-wide methylation information provides a workflow that seamlessly enables wider translational epigenetic research.

Indexed as

DNA MethylationEpigenomicsGenome-Wide Association StudyHigh-Throughput Nucleotide SequencingPromoter Regions, GeneticCpG IslandsFemaleHumansMaleMutL Protein Homolog 1Reproducibility of ResultsSensitivity and SpecificityMLH1 protein, humanMutL Protein Homolog 1

Identifiers

PMID31881335
PMCPMC7103764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.